Nat Commun 13 Gilroy C, Capozzi ME, Varanko AK, Tong J, Dalessio DA et al (2020) Sustained release of a GLP-1 and FGF21 dual agonist from an injectabledepot protects mice from obesity and hyperglycemia
Vcuttaki glutatyon seviyeleri, yetersiz beslenme, evresel toksinler ve stres gibi eitli faktrler nedeniyle azalabilir
Severe Gastrointestinal Disease Individuals with high-risk GI conditions, like Crohns, ulcerative colitis, or bowel blockages, might not tolerate retatrutide
doi: 10.3390/ijms22147475 78 van OostveenWMde LangeECM
Because retatrutide is not yet approved, post-marketing surveillance data are not yet available
Inborn Errors of Metabolism